These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 10343986

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improving the quality of pain treatment by a tailored pain education programme for cancer patients in chronic pain.
    de Wit R, van Dam F, Loonstra S, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, Duivenvoorden H, Huijer Abu-Saad H.
    Eur J Pain; 2001; 5(3):241-56. PubMed ID: 11558980
    [Abstract] [Full Text] [Related]

  • 4. Stop the pain! A nation-wide quality improvement programme in paediatric oncology pain control.
    Zernikow B, Hasan C, Hechler T, Huebner B, Gordon D, Michel E.
    Eur J Pain; 2008 Oct; 12(7):819-33. PubMed ID: 18222100
    [Abstract] [Full Text] [Related]

  • 5. Use of strong opioids in advanced cancer pain: a randomized trial.
    Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G.
    J Pain Symptom Manage; 2004 May; 27(5):409-16. PubMed ID: 15120769
    [Abstract] [Full Text] [Related]

  • 6. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management.
    Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P.
    J Clin Oncol; 2004 May 01; 22(9):1713-20. PubMed ID: 15117994
    [Abstract] [Full Text] [Related]

  • 7. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M, Walker-Corkery E, Barry MJ.
    J Natl Cancer Inst Monogr; 2004 May 01; (33):78-101. PubMed ID: 15504921
    [Abstract] [Full Text] [Related]

  • 8. An educational implementation of a cancer pain algorithm for ambulatory care.
    Du Pen AR, Du Pen S, Hansberry J, Miller-Kraybill B, Millen J, Everly R, Hansen N, Syrjala K.
    Pain Manag Nurs; 2000 Dec 01; 1(4):116-28. PubMed ID: 11709865
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improving pain outcomes of hospice patients with cancer.
    Holzheimer A, McMillan SC, Weitzner M.
    Oncol Nurs Forum; 1999 Oct 01; 26(9):1499-504. PubMed ID: 11064881
    [Abstract] [Full Text] [Related]

  • 12. Opioids and cancer survivors: issues in side-effect management.
    Palos GR.
    Oncol Nurs Forum; 2008 Nov 01; 35 Suppl():13-9. PubMed ID: 18980935
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
    Paulós CP, Nygren CE, Celedón C, Cárcamo CA.
    Ann Pharmacother; 2005 May 01; 39(5):939-43. PubMed ID: 15827075
    [Abstract] [Full Text] [Related]

  • 17. Teaching the basics of clinical pharmaceutical care: innovative pharmacy workshops at the University of Wisconsin and the University of Nebraska.
    Keller DR, O'Dell DV, Skochelak SE, Cochran GL, Shull SJ, Gjerde CJ.
    Fam Med; 2004 Jan 01; 36 Suppl():S89-92. PubMed ID: 14961409
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T.
    Clin Ther; 2009 Jun 01; 31(6):1177-91. PubMed ID: 19695386
    [Abstract] [Full Text] [Related]

  • 20. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug 01; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.